1 WBS for New Compound Development Project
1.1 Project Initiation
1.1.1 Decision to Develop Business Case
1.1.2 Business Case
1.1.3 Project Initiation Decision
1.2 Marketing/Sales Support
1.2.1 Market Research Program
1.2.2 Branding Program
1.2.3 Pricing Program
1.2.4 Sales Development Program
1.2.5 Other Marketing/Sales Support
1.3 Regulatory Support
1.3.1 IND Submission
1.3.1.1 Pre-IND Meeting
1.3.1.2 IND Preparation
1.3.1.2.1 Preclinical Package
1.3.1.2.2 Clinical Package
1.3.1.2.3 Clinical Pharmacology Package
1.3.1.2.4 CM&C Package
1.3.1.3 IND Submission
1.3.2 End of Phase 2 Meeting
1.3.2.1 Pre-Meeting Package
1.3.2.2 End of Phase 2 Meeting
1.3.3 BLA/NDA Submission
1.3.3.1 Pre-BLA/NDA Meeting
1.3.3.2 BLA/NDA Preparation
1.3.3.2.1 Preclinical Package
1.3.3.2.2 Clinical Package
1.3.3.2.3 Clinical Pharmacology Package
1.3.3.2.4 CM&C Package
1.3.3.3 BLA/NDA Submission
1.3.3.4 Advisory Committee Meeting
1.3.3.5 FDA review support
1.3.3.6 Pre-Approval Inspection
1.3.3.7 Approval
1.3.4 Post-approval Regulatory Support Program
1.3.4.1 Annual Reports
1.3.4.2 Adverse Event Reporting
1.3.4.3 Post-market Commitment Administration
1.4 Lead Identification Program
1.4.1 Hypothesis Generation
1.4.2 Assay Screening
1.4.3 Lead Optimization
1.4.4 Other Discovery Support
1.5 Clinical Pharmacology Support
1.5.1 Pharmacokinetic Study(ies)
1.5.2 Drug Interaction Study(ies)
1.5.3 Renal Effect Study(ies)
1.5.4 Hepatic Effect Study(ies)
1.5.5 Bioequivalency Study(ies)
1.5.6 Other Clinical Pharmacology Study(ies)
1.6 Preclinical Program
1.6.1 Tox/ADME Support
1.6.1.1 Non-GLP Animal Studies
1.6.1.2 Bioanalytical Assay Development
1.6.1.3 ADME Evaluations
1.6.1.4 Acute Toxicological Studies
1.6.1.5 Sub-Chronic Toxicological Studies
1.6.1.6 Chronic Toxicological Studies
1.6.1.7 Other Tox/ADME Support
1.6.2 Clinical Pharmacology Support
1.6.2.1 Pharmacokinetic Study(ies)
1.6.2.2 Drug Interaction Study(ies)
1.6.2.3 Renal Effect Study(ies)
1.6.2.4 Hepatic Effect Study(ies)
1.6.2.5 Bioequivalency Study(ies)
1.6.2.6 Other Clinical Pharmacology Study(ies)
1.7 Phase I Clinical Study Program
1.7.1 Pharmacokinetic/Pharmacodynamic Study(ies)
1.7.2 Dose Ranging Study(ies)
1.7.3 Multiple Dose Safety Study(ies)
1.7.3.1 Pre-Enrollment Activities
1.7.3.2 Enrollment
1.7.3.3 Treatment
1.7.3.4 Follow-up
1.7.3.5 Data Management
1.7.3.6 Data analysis
1.7.3.7 Study Report1.10
1.8 Phase II Clinical Study Program
1.8.1 Multiple Dose Efficacy Study(ies)
1.8.2 Other Clinical Study(ies)
1.9 Phase III Clinical Study Program
1.9.1 Pivotal Registration Study(ies)
1.9.2 Other Clinical Study(ies)
1.10 Submission/Launch Phase
1.10.1 Pre-Launch preparation
1.10.2 Launch
1.10.3 Post-Launch Support
1.11 Phase IV/Commercialization Clinical Study Program
1.11.1 Investigator-Sponsored Studies
1.11.2 Registry Studies
1.12 Legal Support
1.12.1 Publications
1.12.2 Patents/Intellectual Property
1.12.3 Trademarks
1.12.4 Other Legal Support
1.13 Program Management Support
1.13.1 Program-Level Project Management
1.13.2 Preclinical Project Management
1.13.3 Clinical Project Management
1.13.4 CM&C Project Management
1.13.5 Other Project Management Support